Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · Real-Time Price · USD
96.62
+1.81 (1.91%)
Nov 21, 2024, 4:00 PM EST - Market closed
Blueprint Medicines Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 434.42 | 249.38 | 204.04 | 180.08 | 793.74 | 66.51 | Upgrade
|
| Revenue Growth (YoY) | 100.93% | 22.22% | 13.30% | -77.31% | 1093.37% | 49.39% | Upgrade
|
| Cost of Revenue | 12.93 | 12.8 | 26.76 | 25.74 | 0.43 | - | Upgrade
|
| Gross Profit | 421.48 | 236.58 | 177.28 | 154.35 | 793.31 | 66.51 | Upgrade
|
| Selling, General & Admin | 342.14 | 295.14 | 237.37 | 195.29 | 157.74 | 96.39 | Upgrade
|
| Research & Development | 355.3 | 427.72 | 477.42 | 601.03 | 326.86 | 331.45 | Upgrade
|
| Operating Expenses | 697.43 | 722.86 | 714.79 | 796.33 | 484.6 | 427.84 | Upgrade
|
| Operating Income | -275.95 | -486.28 | -537.52 | -641.98 | 308.71 | -361.33 | Upgrade
|
| Interest Expense | -50.3 | -36.26 | -17.75 | - | - | - | Upgrade
|
| Interest & Investment Income | 7.28 | - | - | 3.75 | 7.07 | 8.78 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | - | - | - | -0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.39 | -0.95 | 2 | -1.49 | -0.37 | - | Upgrade
|
| EBT Excluding Unusual Items | -318.58 | -523.48 | -553.26 | -639.72 | 315.41 | -352.64 | Upgrade
|
| Gain (Loss) on Sale of Investments | 17.47 | 17.47 | 0.98 | -1.36 | -0.47 | 4.95 | Upgrade
|
| Pretax Income | -127.43 | -506.02 | -552.28 | -641.08 | 314.94 | -347.69 | Upgrade
|
| Income Tax Expense | 0.62 | 0.97 | 5.24 | 3 | 1.06 | - | Upgrade
|
| Net Income | -128.05 | -506.98 | -557.52 | -644.09 | 313.88 | -347.69 | Upgrade
|
| Net Income to Common | -128.05 | -506.98 | -557.52 | -644.09 | 313.88 | -347.69 | Upgrade
|
| Shares Outstanding (Basic) | 62 | 61 | 60 | 59 | 55 | 48 | Upgrade
|
| Shares Outstanding (Diluted) | 62 | 61 | 60 | 59 | 56 | 48 | Upgrade
|
| Shares Change (YoY) | 3.11% | 1.54% | 1.92% | 4.18% | 17.44% | 9.03% | Upgrade
|
| EPS (Basic) | -2.06 | -8.37 | -9.35 | -11.01 | 5.76 | -7.27 | Upgrade
|
| EPS (Diluted) | -2.06 | -8.37 | -9.35 | -11.01 | 5.59 | -7.27 | Upgrade
|
| Free Cash Flow | -250.52 | -452.91 | -511.2 | -301.74 | 383.88 | -292.03 | Upgrade
|
| Free Cash Flow Per Share | -4.03 | -7.48 | -8.57 | -5.16 | 6.83 | -6.11 | Upgrade
|
| Gross Margin | 97.02% | 94.87% | 86.88% | 85.71% | 99.95% | 100.00% | Upgrade
|
| Operating Margin | -63.52% | -194.99% | -263.44% | -356.50% | 38.89% | -543.25% | Upgrade
|
| Profit Margin | -29.48% | -203.30% | -273.24% | -357.67% | 39.54% | -522.75% | Upgrade
|
| Free Cash Flow Margin | -57.67% | -181.61% | -250.54% | -167.56% | 48.36% | -439.06% | Upgrade
|
| EBITDA | -262.13 | -474.61 | -525.78 | -635.5 | 315.27 | -356.07 | Upgrade
|
| EBITDA Margin | -60.34% | -190.32% | -257.69% | - | 39.72% | - | Upgrade
|
| D&A For EBITDA | 13.82 | 11.67 | 11.74 | 6.48 | 6.56 | 5.26 | Upgrade
|
| EBIT | -275.95 | -486.28 | -537.52 | -641.98 | 308.71 | -361.33 | Upgrade
|
| EBIT Margin | -63.52% | -194.99% | -263.44% | - | 38.89% | - | Upgrade
|
| Effective Tax Rate | - | - | - | - | 0.34% | - | Upgrade
|
| Revenue as Reported | 434.42 | 249.38 | 204.04 | 180.08 | 793.74 | 66.51 | Upgrade
|
| Advertising Expenses | - | 16.9 | 18.1 | 13.5 | 9.4 | 3.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.